Toxic Fungi Could Threaten Millions of Lives Within 15 Years
A new study analyzing different climate scenarios discovered that toxic fungi will likely spread into new areas in the future, possibly threatening millions.
Life-sustaining fungi that break down plant and animal matter could also be at risk of extinction in some of the warmest regions of the Earth—particularly on the African continent.
It's estimated that scientists have only cataloged about 10 percent of all fungi on Earth, so unknown surprises would likely be in store as fungi spread beyond their historic regions.
When writing about climate, lots of ink—or pixels, in a 21st-century context—is spent talking about the potentially devastating impacts that climate change will have on plant and animal life. However, little is mentioned about the kingdom Fungi. Hundreds of thousands of species of fungi have been described, but that's likely only 10 percent of the total number of fungal species that exist on Earth. These species include everyone's delicious favorites, but also some more dangerous species that can cause toxic infections in animals and agricultural crops.
So, in a new study from the University of Manchester, scientists asked the question of what rising global temperatures could mean for the proliferation of some of these meaner mycelia. In a paper published on the preprint platform ResearchSquare, Norman van Rhijn, the lead author of the study, and his team describe what our fungal future has in store.
'Changes in environmental factors, such as humidity and extreme weather events, will change habitats and drive fungal adaptation and spread,' van Rhign said in a press statement. 'We've already seen the emergence of the fungus Candida auris due to rising temperatures, but, until now, we had little information of how other fungi might respond to this change in the environment.'
The researchers analyzed the effects of rising temperatures on infection-causing fungi using different climate scenarios up to the year 2100. The study showed that within 15 years, if the world still relies on mostly fossil fuels instead of clean energy, fungi like Aspergillus flavus—a cause of agricultural rot that also produces mycotoxins that are harmful to mammals—will spread by 16 percent, which would put an additional 1 million people at risk of infection in Europe alone. This is largely because A. flavus is more thermotolerant than other fungi, meaning that it can thrive in hot, humid climates where other fungi simply could not.
Unfortunately, this proliferation is relatively tame compared to Aspergillus fumigatus, which would increase its range by 77.5 percent and put an additional nine million people in Europe at risk under this worst-case scenario. While described as a weak pathogen in previous studies, A. fumigatus can cause a severe or even fatal infection for people with immune deficiencies.
'Fungi are relatively under researched compared to viruses and parasites, but these maps show that fungal pathogens will likely impact most areas of the world in the future,' van Rhign said in a press statement. 'Raising awareness and developing effective interventions for fungal pathogens will be essential to mitigate the consequences of this.'
While the spread of these toxic fungi—whose infections are hard to avoid, as they mostly travel in the air we breathe— the inverse may also be a cause for concern. Some life-sustaining fungi, responsible for breaking down plant and animal matter, may not be able to survive in some of the hottest parts of the world (especially on the African continent). It's basically a one-two punch of bad news.
Additionally, the study only examined the roughly 10 percent of the fungi we know about, so even more infections or health concerns could arise from surprising sources currently unknown to us. Though it has yet to be peer-reviewed, the paper details compelling evidence that our fungal future is a dismal one unless we seriously curtail carbon emissions in the coming years. Transitioning to a clean energy future is the best path forward—for all of the plants, animals, and overlooked fungus among us.
You Might Also Like
Can Apple Cider Vinegar Lead to Weight Loss?
Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
3 hours ago
- The Hill
Candida auris cases nearly triple as deadly fungus spreads to new states
(NEXSTAR) – The number of Candida auris infections reported to the Centers of Disease Control and Prevention this year has nearly tripled in the past three and a half months as health care providers struggle to contain the the drug-resistant and deadly fungus. At the end of April, the CDC had recorded 1,052 Candida auris. By Aug. 9, the last week of available data, the total number of cases had grown to 2,809 cases across 21 states, surpassing the number of cases we saw at this time last year. Candida auris, also called C. auris, was first identified in the U.S. fewer than 10 years ago. Since then, the number of cases have increased every year. The CDC has considered the fungus ' an urgent antimicrobial resistance threat ' because it has developed ways to defeat the drugs that are designed to kill it. Fungus labeled 'urgent threat' by CDC is spreading rapidly, hospital study finds In the past three months, Kansas, Kentucky, Mississippi and Tennessee recorded their first cases, joining 17 other states that were already tracking the fungus' spread in 2025. Of the roughly 2,800 cases reported so far this year, about a quarter (or 727 cases) were in Texas alone. Some of the biggest spread was in the Midwest, where cases in a handful of states more than doubled since April. Illinois reported 362 cases, Michigan reported 342, Ohio had 291 and Indiana had 164. Candida auris can be hard or impossible to be treat because antifungal medications aren't effective. 'If you get infected with this pathogen that's resistant to any treatment, there's no treatment we can give you to help combat it. You're all on your own,' Melissa Nolan, an assistant professor of epidemiology and biostatistics at the University of South Carolina, told Nexstar. What still causes the plague in the US? People with a healthy immune system may be able to fight off infection on their own, but the fungus mainly spreads in health care settings, where people are sick and vulnerable. The fungus can survive on surfaces, like countertops, doorknobs, or even people's skin, for a long time before spreading to vulnerable patients. People with catheters, breathing tubes, feeding tubes and PICC lines are at the highest risk because the pathogen can enter the body through these types of devices. A study published last month, which looked at patients with Candida auris primarily in Nevada and Florida, found more than half of patients required admission to the intensive care unit and more than one-third needed mechanical ventilation. More than half of patients, whose average age was between 60 and 64, also needed a blood transfusion. In the past, the CDC estimated that 'based on information from a limited number of patients, 30–60% of people with C. auris infections have died. However, many of these people had other serious illnesses that also increased their risk of death.'
The Onion
a day ago
- The Onion
Study: Elephants Only Other Species Capable Of Leveraging Synergies In Brand Portfolio
ITHACA, NY—In a groundbreaking study published in the journal Animal Behaviour , researchers at Cornell University revealed Monday that elephants are the only known nonhuman species capable of leveraging synergies across a diversified brand portfolio. 'Conventional wisdom has long held that leveraging omnibrand fluidity to unlock cross-platform capital efficiencies was a behavior unique to humans, but in the wild we have observed multiple African elephant groups with a highly evolved capacity for optimizing cross-vertical integration through holistic brand harmonization at scale,' said Professor Mia Sherin, who noted that elephant corporate structures are matriarchal, and females consistently serve as project managers across multiplatform activations, seamlessly executing cross-functional touchpoints and asynchronous ideation cycles. 'This marks one of the most advanced examples of nonhuman tool use ever recorded. We've observed elephants utilizing Microsoft Excel for longitudinal KPI tracking, assembling low-fidelity mood boards to map brand essence, and creating rudimentary LinkedIn profiles to strengthen B2B positioning. In one case, a juvenile even led a rapid-fire ideation sprint that resulted in a fully actualized multichannel activation plan. This study brings us one step closer to the dream of true interspecies communication, should we ever manage to put some time down on their calendars to connect over a coffee.' At press time, Sherin's team traveled back to Tanzania to study how different elephant groups mourn, as they are thought to be the only other animals known to grieve their profit losses.
Business Wire
a day ago
- Business Wire
Butterfly Network Joins Research Project Studying the Impact of AI-Assisted POCUS on Early Tuberculosis Detection in Sub-Saharan Africa
BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)-- Butterfly Network, Inc. ('Butterfly', 'the Company') (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound, today announced its role in the international research study CAD LUS4TB that will evaluate the impact of AI-assisted point-of-care ultrasound (POCUS) on tuberculosis (TB) triage in under-resourced settings. For patients in regions such as Sub-Saharan Africa (SSA) with no access to ultrasound in primary care, there is a critical need for accessible diagnostic tools. WHO data suggests that 2.5 million people fell ill with TB in Africa in 2022, accounting for a quarter of new TB cases worldwide, and over 33% of TB deaths occurred in the African region. Butterfly is part of the CAD LUS4TB consortium alongside 10 research institutions in Africa and Europe. The consortium is trialing a new AI algorithm, using Butterfly's software development platform. The program automates image classification for TB from images obtained using Butterfly's portable ultrasound devices. AI-aided POCUS will be used to help frontline healthcare workers quickly and more accurately detect TB at point of care in an initial trial in the SSA region. The European Union's Global Health EDCTP3 Joint Undertakings has provided €10 million in funding for this work. The trial initiates in September and will involve 3,000 adult patients across SSA. Patients will be treated by non-radiologist healthcare workers supported by AI-led POCUS to identify likely TB indicators. This approach empowers healthcare workers to assess patients for TB without needing extensive ultrasound training or access to lab testing. 'Butterfly is proud to continue improving global health equity through our role in this project. Patients in lower-resource settings need easier access to diagnostic imaging to detect and treat deadly diseases such as TB before it claims more lives,' said Dr. Sachita Shah, VP of Global Health, Butterfly Network. 'We believe that this study has the capacity to demonstrate that faster, safer, more accessible triage with AI-enabled POCUS can drastically reduce morbidity and mortality from TB and other lung diseases in low- and middle-income countries.' The CAD LUS4TB initiative also seeks to generate an evidence-driven policy that supports AI-aided lung ultrasound in TB management, with the long-term goal of the technology's incorporation into national healthcare policies and systems. Powered by the company's Ultrasound-on-Chip™ technology, Butterfly delivers sharp image quality and powerful AI capabilities in a single handheld probe. Butterfly's portable hardware, coupled with the company's partner platform for software development, uniquely positions Butterfly POCUS as a suitable vehicle for deploying new, innovative AI algorithms to diagnose leading causes of global mortality, including TB. The study is the latest innovation in Butterfly's ongoing commitment to improving access to ultrasound for healthcare professionals and patients globally, particularly in underserved areas. Butterfly previously supported the TrUST study, an international prospective trial which developed AI algorithms for diagnosis of TB using Butterfly. Butterfly's Global Health Program works with hundreds of non-profit and humanitarian organizations in over 115 countries to provide sustainable and equitable digital health solutions to the world's most vulnerable populations. About Butterfly Network Butterfly Network, Inc. (NYSE: BFLY) is a healthcare company driving a digital revolution in medical imaging with its proprietary Ultrasound-on-Chip™ semiconductor technology and ultrasound software solutions. In 2018, Butterfly launched the world's first handheld, single-probe, whole-body ultrasound system, Butterfly iQ. The iQ+ followed in 2020, and the iQ3 in 2024, each with improved processing power and performance by leveraging Moore's Law. The iQ3 earned Best Medical Technology at the 2024 Prix Galien USA Awards, a prestigious honor and one of the highest accolades in healthcare. Butterfly's innovations have also been recognized by Fierce 50, TIME's Best Inventions and Fast Company's World Changing Ideas, among other achievements. Butterfly combines advanced hardware, intelligent software, AI, services, and education to drive adoption of affordable, accessible imaging. Clinical publications demonstrate that its handheld ultrasound probes paired with Compass™ enterprise workflow software, can help hospital systems improve care workflows, reduce costs, and enhance provider economics. With a cloud-based solution that enables care anywhere through next-generation mobility, Butterfly aims to democratize healthcare by addressing critical global healthcare challenges. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about Butterfly's Global Health Program, please visit:
